Breast cancer diagnostic solutions Deliver diagnostic confidence
|
|
- Christian Townsend
- 6 years ago
- Views:
Transcription
1 Breast cancer diagnostic solutions Deliver diagnostic confidence
2 2 Breast cancer diagnostic solutions Roche Tissue Diagnostics is committed to improving outcomes in breast cancer Breast cancer...the most common cancer type and cause of cancer-related deaths in women 1...annually claims more than 500,000 lives worldwide 1...in the US, 1 out of 8 women will develop invasive breast cancer during their lifespan 2 Breast cancer remains a significant scientific, clinical and societal challenge. Everyone s cancer diagnosis is as distinct as the person it affects. Breast cancer is heterogeneous in nature and has distinct biological, pathological and genetic diversity. Biomarkers can help identify patient subgroups most likely to benefit from a specific treatment. Diagnostic and prognostic descriptions of subtypes, guided by biomarker results, have become increasingly more sophisticated over the past decades.
3 Breast cancer diagnostic solutions 3 Precision medicine: The right test at the right time facilitates differential diagnosis Evidence supports that breast cancer tumors can be grouped into subtypes with distinct clinical profiles and treatment options. 3 Understanding the diversity in breast cancer allows for stratification of patient subgroups. Individual biomarkers (or panels of biomarkers) characterize subtypes, confirm origin of tissue, differentiate primary from metastatic tumor and provide prognostic and predictive information. 4 Biomarkers play an important role in the detection and management of patients 5 Biomarkers are the most precise way of identifying intrinsic subtypes 6 Failure to correctly stratify a patient can lead to unnecessary and costly exposure to therapeutics, prevent the delivery of the most beneficial treatment and may reduce the degree of positive outcomes 7,8,9 Three reasons to choose Roche Tissue Diagnostic s Solutions Our breast cancer diagnostics deliver on three key benefits that are valued by pathology professionals: 1. Clinical utility With proven accuracy 15,21 our breast cancer diagnostic assays help you identify patients other assays can miss 7,9,16,17 so you can deliver the right test, with clinical confidence in the shortest possible time. Our mission is to improve the lives of all patients afflicted with cancer. We are committed to empowering you in your quest to elevate the standard of care. 2. Analytical performance Specific and sensitive rabbit monoclonal antibodies, bestin-class probes, and powerful detection systems help you diagnose precisely and confidently. 3. Testing efficiency Our comprehensive breast cancer workflow solution delivers fully automated assays on market-leading platforms, with digital pathology and workflow solutions that free resources, reduce labor costs, and reduce time to results.
4 4 Breast cancer diagnostic solutions Biomarker status helps to identify patient groups most likely to respond to a specific treatment HER2 overexpression accounts for 15% to 20% of all breast cancers. Tumors that overexpress the HER2 gene are associated with more rapid growth compared to HER2 negative tumors. 6,10,12 Estrogen Receptor (ER) and Progesterone Receptor (PR) positive tumors account for approximately 74% of all breast cancer tumors. Dual positive hormone receptor tumors are usually slow growing and less aggressive. 5 Luminal A tumors have favorable short-term prognosis and show favorable response to hormonal therapy. 5 Luminal B tends to be more aggressive and higher grade than Luminal A. 5 In early breast cancer, moderate to strong PR expression is an aid to differentiate between Luminal A and B tumors. 12 Classifications of IHC subtypes: St. Gallen Consensus 12 Erb-B2 overexpression (non-luminal) Luminal A Luminal B (Her2 +) Luminal B (Her2 -) Basel like (Ductal, TN) HER2 + Overexpressed or amplified ER PR - + Any Negative or low - Ki-67 Low Any High Key + positive - negative This chart is not for diagnostic use. It represents staining patterns that are associated with breast cancers based on St. Gallen Expert Consensus, TN triple negative
5 Breast cancer diagnostic solutions 5 Pathology assessments play a critical role in breast cancer management Breast cancer management is complex and biomarkers play an integral role in determining the status of the tumor. IHC and ISH biomarkers help facilitate decision-making for subsequent therapeutic options. 3,6,10 The benefit of chemotherapy is dependant on multiple factors: Tumor size, lymph node involvement and the presence of biomarkers. 5 Multiple tests used to determine treatment 11 HER2 status Treatment decision Hormone receptor status HER2+ Hormone therapy * and targeted therapy ER+ and/or PR+ HER2- HER2- Hormone therapy * Breast cancer histology HER2+ Targeted therapy* ER- and/or PR- Non-targeted therapy* Source: Diagram is developed based on NCCN Guideline for Invasive Breast Cancer 11 * Targeted therapy can include chemotherapy with trastuzumab for HER2 positive patients, hormone therapy is for ER and/or PR positive patients, non-targeted therapy refers to chemotherapy for patients with triple negative status.
6 6 Breast cancer diagnostic solutions Provide confidence in your lab with Roche Tissue Diagnostics HER2 testing Breast carcinoma HER2 Dual ISH non-amplified, Magnification: 40X INFORM HER2 Dual ISH DNA Probe cocktail INFORM HER2 Dual ISH DNA Probe cocktail is designed to detect amplification of the HER2 gene and is indicated as an aid in the assessment of patients for whom Herceptin treatment is being considered. 13 ISH utilized as a reflex for IHC equivocal (2+) results Patient breast tissue sample Standardized and validated test platforms Adequate (formalin) fixation (6-72h) Results are easily scored using brightfield microscopy in-house with familiar technologies HER2 gene amplification assessment over the entire slide not just a pre-selected area facilitates scoring and identification of heterogeneity Simultaneous morphological assessment independent of H&E stain Archivable results allow for easy maintenance and simplifies consults in difficult cases Enhanced technical support tools including clear, consolidated guidance on best practices and streamlined training H&E stain Primary staining shows morphologic changes IHC Controls passed No significant staining in normal epithelium No faint or partial staining a Weak complete staining a Greater than 10% Intense complete staininga Greater than 10% ISH Report as HER2 positive oncologist for HER2-targeted therapies 2 2 a) Membrane staining
7 7 Breast cancer diagnostic solutions In a recent publication7 assessing the socioeconomic impact of inaccurate HER2 breast cancer testing, laboratory-developed in vitro diagnostic (IVD) were compared to U.S. Food and Drug Administration-approved IVD, found a cost benefit in using an approved IVD test. Breast carcinoma HER2 (4B5) positive, Score: 3+ Magnification: 40X HER2/neu (4B5)* Rabbit Monoclonal Primary Antibody The use of pre-dilutedpathway HER2 (4B5),14 in combination with the fully automated BenchMark IHC/ISH slide staining instrument, standardizes all IHC processes from baking through staining, and reduces the possibility of human error. It also minimizes inherent variability resulting from individual reagent dilution and other processes found in manual and semi-automated IHC methods. The PATHWAY HER2 (4B5) Primary Antibody empowers you to: Achieve consistently high proficiency assessment scores with HER2 (4B5) antibody, compared to other clones15 Employ the most widely adopted and reliable HER2-IHC primary antibody15 High concordance with HER2 FISH16,17 Proportion of sufficient stains (optimal or good) HER2 (4B5): Consistent high performance* competitor 1 concentrate competitor 1 ready-to-use competitor 2 ready-to-use HER2 4B5* (pre-dilute) Assessments *Data refers to PATHWAY and VENTANA products. Based on 5 years of data from a leading external quality assessment scheme. Retrieved from
8 8 Breast cancer diagnostic solutions Provide an aide in the management, prognosis and prediction of therapy outcomes of breast cancer Breast carcinoma ER (SP1) positive, Magnification: 40X Breast carcinoma PR (1E2) positive, Magnification: 40X CONFIRM anti-estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody and CONFIRM anti-progeserone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody ER is a powerful predictor of response to hormone therapy (such as Tamoxifen) and clinical outcome of breast cancer patients. PR status can add additional prognostic and predictive value to ER status by providing an independent and significant tool for predicting hormone therapy response and clinical outcome. 18 Indicated as an aid in patient management, prognosis, and the prediction of therapy outcomes in breast cancer 19,20 Rapid and consistent results delivered through fully automated platforms and digital pathology solutions ER (SP1) is a significant predictor of disease-specific survival 9,21 Achieve consistently high proficiency assessment scores with ER (SP1) antibody, compared the other clones 15 PR (1E2) antibody provides significant value as a prognostic factor and response prediction of hormone therapy, even in ER negative patients 18 ER (SP1): Consistent high performance* competitor 1 Proportion of sufficient stains (optimal or good) competitor 2 competitor 3 competitor 4 competitor 5 competitor 6 ER2 (SP1) (pre-dilute) Assessments *Based on 5 years of data from a leading external quality assessment scheme. Retrieved from
9 Breast cancer diagnostic solutions 9 Supporting breast cancer diagnostics Breast carcinoma Ki-67 (30-9) stained Magnification: Low Breast carcinoma E-cadherin (36) stained Magnification: 40X CONFIRM anti-ki-67 (30-9) Rabbit Monoclonal Primary Antibody CONFIRM Ki-67 (30-9) Antibody is directed against C-terminal portion of Ki-67 antigen. Staining for Ki-67 can be used to aid in assessing the proliferative activity of normal and neoplastic tissue. With intense nuclear staining and no adipose (K2) or cell membrane staining (MIB-1), CONFIRM Ki-67 (30-9) rabbit monoclonal antibody can help deliver a confident assessment of tumor aggressiveness. 22,23 Uncontrolled proliferation is a hallmark of malignancy. The 2013, St Gallen Expert Concensus 12 found that the degree of proliferative activity in breast cancer helped differentiate Luminal A from Luminal B tumors. VENTANA anti-e-cadherin (36) Mouse Monoclonal Primary Antibody Ventana E-cadherin (36) antibody is directed against the cytoplasmic domain of the human transmembrane protein E-cadherin expressed as a part of the cell-cell adhesion complex in epithelial tissues. 24 Reduction or loss of expression is associated with invasive carcinoma and possibly metastasis in a variety of carcinomas. This antibody may be used to aid in the differentiation of in-situ and/or invasive lobular carcinoma from in situ and/or invasive ductal carcinoma of the breast. CONFIRM p53 (DO-7) Primary Antibody CONFIRM p53 (DO-7) is used in conjunction with VENTANA Companion Algorithm p53 (DO-7) image analysis application using the VENTANA iscan Coreo Au scanner and VIRTUOSO software. 25 GATA3 (L50-823) Mouse Monoclonal Primary Antibody Use of this antibody is indicated as an aid in the identification of breast carcinomas within the context of an antibody panel, clinical history and a qualified pathologist. 26 GATA3 expression is primarily seen in breast carcinoma and urothelial carcinoma and only rarely found in tumors from other organs. 26 Mammaglobin (31A5) Rabbit Monoclonal Antibody Use of this antibody is indicated as an aid in the identification of metastatic breast carcinomas within the context of an antibody panel, clinical history and a qualified pathologist. 27 When combined with other breast-restricted markers such as GCDFP-15, an overall sensitivity for breast carcinoma of 84% has been achieved. 27
10 10 Breast cancer diagnostic solutions Digital pathology: Virtual consultation, image analysis and education Roche Digital Pathology is transforming the practice of pathology by developing innovative technologies that deliver medical value, inform decision making and improve cancer care. The integrated solution consists of high-quality scanners, image analysis software, image and workflow management software and education applications, all working together globally to optimize laboratories. Digital pathology enables more efficient and informed treatment decisions for patients enchanting care by eliminating the boundaries of time and distance. Your benefit Virtual consultation Maximize pathologist time Enable flexibility for tumor boards, case sharing and collaboration Enable fast turnaround time for expert opinions Provide access to sub-specialists Image analysis Build clinical confidence with US and CE-IVD validated Companion Algorithm image analysis software Facilitate consistent, objective interpretations for breast IHC verified by a pathologist for every patient Education Enrich and accelerate learning in a collaborative environment Allow students to review material anywhere, anytime, from the device of their choice Product features VENTANA Virtuoso image and workflow management software Anytime, anywhere access to slide images Optimize digital workflow and decision-making environment Web-based application to support remote consults and image analysis VENTANA Companion Algorithm image analysis software US and CE-IVD validated image analysis algorithms for the full breast panel: HER2, ER, PR, Ki-67 and p53 Semi-quantitative scores for markers requiring cell counts Fully validated as part of a systems approach includes reagents, staining platforms, scanners and software VENTANA iscan Coreo slide scanner Intended for low- to mid- volume scanning sites Brightfield scanning capability (160 slide capacity) at various magnifications 4x, 10x, 20x, 40x Live mode (remotely controlled microscope) VENTANA iscan HT slide scanner Intended for high-volume scanning sites Brightfield scanning capability (360 slide capacity) at various magnifications 20x, 40x Continuous random access and STAT processing with no workflow interruption VENTANA Vector education and collaboration software Support education and collaboration with digital images Standardize content and eliminate sharing resources (slides or microscopes) Allow students to review material anywhere, anytime, from the device of their choice (mobile-capable on ios and Android devices)
11 Breast cancer diagnostic solutions 11 World-class antibodies to stratify breast cancer Product Name Catalog no. Ordering code Tests CA-125 (OC125) Mouse Monoclonal Antibody Calponin-1 (EP798Y) Rabbit Monoclonal Antibody E-cadherin (36) Mouse Monoclonal Primary Antibody, VENTANA E-cadherin (EP700Y) Antibody Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody, CONFIRM Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody, CONFIRM FOXA1(2F83) Mouse Monoclonal Primary Antibody GATA3 (L50-823) Mouse Monoclonal Primary Antibody GCDFP-15 (EP1582Y) Rabbit Monoclonal Antibody GLIAL Fibrillary Acidic Protein (EP672Y) Rabbit Monoclonal Antibody Growth Hormone (polyclonal) Human Placental Lactogen (hpl) (polyclonal) HER2 Dual ISH DNA Probe Cocktail, INFORM HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody, PATHWAY Her-2/neu (4B5) Rabbit Monoclonal Primary Antibody, VENTANA Ki-67 (30-9) Rabbit Monoclonal Primary Antibody, CONFIRM Mammaglobin (31A5) Rabbit Monoclonal Antibody P53 (BP53-11) Primary Antibody P53 (DO-7) Primary Antibody, CONFIRM P57 (Kp10) Mouse Monocloncal Primary Antibody p63 (4A4) Mouse Monoclonal Primary Antibody, VENTANA P120 CATENIN (98) Mouse Monoclonal Primary Antibody, VENTANA PAX8 (MRQ-50) Mouse Monoclonal Primary Antibody PLAP (NB10) Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody PTEN (SP218) Rabbit Monoclonal Primary Antibody Topoisomerase IIα (JS5B4) Rabbit Monoclonal Primary Antibody Experience the power and confidence that comes from bringing VENTANA breast cancer diagnostics to your practice and patients today. For more information, contact your local Account Manager or visit us at
12 References 1. International Agency for Research on Cancer (IARC) and World Health Organization (WHO). GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in Accessed August 29, U.S. breast cancer statistics Accessed August 29, Parker JS, Mullins M, Cheang M. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8): Zaha, DC. Significance of immunohistochemistry. World J Clin Oncol. 2014;5(3): American Cancer Society: Breast cancer: Facts and figures Web site. acspc pdf Assessed September 19, Purrington KS, Visscher DW, Wang C. Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. Breast Cancer Res Treat [Epub ahead of print] doi: /s Vyberg M, Nielsen S, Røge R, et al. Immunohistochemical expression of HER2 in breast cancer: Socioeconomic impact of inaccurate tests. BMC Health Services Research. 2015;15: Luo D, Smith JA, Meadows NA. et al. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics. Frontiers in Genetics;6 Atricle357: Welsh AW, Harigopal M, Wimberly H, et al. Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5. Appl Immunohistochem Mol Morphol. 2013;2: Wolff AC, Hicks D, Hammond E. Recommendations for Human Epidermal Growth Factor Receptor 2 testing in breast cancer: American Society of Clinical Oncology/ College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013;31(31): NCCN Clinical Practice Guidelines in Oncology. Breast cancer. Version 3, Accessed September 19, Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Annals of Oncology. 2013;24: INFORM HER2 Dual ISH DNA Probe Cocktail Assay Package Insert. 15. NordiQC Assessments. Accessed September 19, Mayr D, et al. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (VENTANA) for VENTANA BenchMark automatic staining system with correlation to results of BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). Virchows Archiv. 2009; 454(3): Brügmann A, Lelkaitis G, Nielsen S, et al. Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC. Appl Immunohistochem Mol Morphol. 2011;19(3): Liu, S, Cchia SK, Mehl, E, et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat. 2010;119: CONFIRM anti-estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody [package insert]. Tucson, AZ: VENTANA Medical. 20. CONFIRM anti-progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody [package insert]. Tucson, AZ: VENTANA Medical Systems, Inc.; Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, et al. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer. Mod Patholo 2013: 26): Leonardo E, Volante M, Barbareschi. et al. Cell membrane reactivity of MIB-1antibody to Ki-67 in human tumors: Fact or artifact? Appl Immunohistochem Mol Morphol. 2007;15(2): Miller R. Ki-67 clone K-2: A useful marker of fat cells and lipoblasts ProPath The Focus-Immunochistochemistry. Published February VENTANA anti-e-cadherin (36) Mouse Monoclonal Primary Antibody [package insert]. Tucson, AZ: VENTANA Medical Systems, Inc.; CONFIRM p53 (DO-7) Primary Antibody. [package insert]. Tucson, AZ: VENTANA Medical Systems, Inc.; GATA3 (L50-823) Mouse Monoclonal Primary Antibody. [package insert]. EN Rev. 0.1 v Mammaglobin (31A5) Rabbit Monoclonal Antibody. [package insert]. EN Rev VENTANA anti-her-2/neu (4B5) Rabbit Monoclonal Primary Antibody Package Insert. Ventana Medical Systems, Inc E. Innovation Park Drive Tucson, AZ USA Ventana Medical Systems, Inc. All trademarks mentioned enjoy legal protection. VENTANA, BENCHMARK, COMPANION ALGORITHM, CONFIRM, ISCAN COREO, VENTANA ISCAN, VENTANA VECTOR and VIRTUOSO are trademarks of Roche. All other trademarks are the property of their respective owners. 6073B 0217 RTDPC-ASFASA-0105
Breast cancer: Antibody selection, protocol optimzation controls and EQA
Breast cancer: Antibody selection, protocol optimzation controls and EQA Workshop in Diagnostic Immunohistochemistry Oud St. Jan/ Old St. John Brugge (Bruges), Belgium June 13th 15nd 2018 Rasmus Røge,
More informationDigital Pathology and CAP Guidelines
Digital Pathology and CAP Guidelines Frequently asked questions The VENTANA family of digital pathology products empowers you with the convenience of a comprehensive image and workflow solution. When used
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationCOMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME
COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME Maria Lunardi MD Anatomic Pathology Fracastoro Hospital San Bonifacio, Verona -Italy HER2-neu
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationOptimization of antibodies, selection, protocols and controls Breast tumours
Optimization of antibodies, selection, protocols and controls Breast tumours Søren Nielsen Project coordinator & Scheme Manager NordiQC Aalborg University Hospital, Denmark Breast panel: GCDFP-15 Mammaglobin
More informationAssessment Run B HER-2 IHC. HER-2/chr17 ratio**
Assessment Run B2 20 HER-2 IHC Material The slide to be stained for HER-2 comprised the following 5 tissues: IHC HER-2 Score* (0, +, 2+,3+) FISH HER-2/chr7 ratio**. Breast ductal carcinoma 0..3 2. Breast
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationHER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationAssessment Run B HER2 IHC
Assessment Run B26 208 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, +, 2+, 3+) FISH: HER2 gene/chr 7 ratio**. Breast carcinoma, no. 2+..3
More information# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer
#1034 - Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer Richard W. Cartun, MS, PhD Andrew Ricci, Jr, MD Department of Pathology Hartford
More informationExternal Quality Assessment of Breast Marker Analysis. NordiQC data
External Quality Assessment of Breast Marker Analysis NordiQC data Søren Nielsen Scheme Manager NordiQC Aalborg University Hospital, Denmark Aalborg 12.06 2015 Markers assessed in NordiQC Predictive markers
More informationAssessment Run B HER2 IHC
Assessment Run B24 2017 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, 1+, 2+, 3+) FISH: HER2 gene/chr 17 ratio** 1. Breast carcinoma, no.
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationProduct Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue
Product Introduction Product Codes: HCL029, HCL030 and HCL031 Issue 1. 180510 Contents Introduction to Estrogen Receptor 2 ER immunohistochemistry 3 Quality control 5 Cell lines as controls 6 Estrogen
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment Run B26 2018 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity* 1. Uterine cervix 80-90% Moderate to strong 2. Tonsil 1-5% Weak
More informationCANCER. Clinical Validation of Breast Cancer Predictive Markers
Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond
More informationMolecular Probes Introducing 14 new probes
Molecular Probes Introducing 14 new probes Gene and Chromosome Probes Dual Colour ISH INFORM HER2 Dual ISH DNA Probe Cocktail Assay Product Part Number INFORM HER2 Dual ISH DNA Probe Cocktail 800-4422
More informationEvaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
More informationThe Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationWelcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016
HER2 TESTING DIAGNOSTIC ACCURACY Can t We Finally Get It Right? Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Seattle, Washington Clinical Professor of Pathology University
More informationBreast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
Breast cancer: IHC classification Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark http://upload.wikimedia.org/wikipedia/commons/1/1a/breast.svg
More informationQuality assurance and quality control in pathology in breast disease centers
Quality assurance and quality control in pathology in breast disease centers Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 1 st IBDC, 28 th January, 2011
More informationKristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD
AJCP / Original Article Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing Increase in Equivocal Results and Utility of Reflex Immunohistochemistry
More informationVENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue
VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue VENTANA anti-mlh1 (M1) Mouse Monoclonal Primary Antibody VENTANA anti-pms2 (A16-4) Mouse Monoclonal Primary Antibody VENTANA
More informationQuantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer
Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine
More informationQuality Assurance and Quality Control in the Pathology Dept.
Quality Assurance and Quality Control in the Pathology Dept. Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 2 nd IBDC, 9 th February, 2012 Pathology as
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationAssessment Run B HER-2
Assessment Run B1 2006 HER-2 The slide to be stained for HER-2 comprised: 1. Cell line JIMT-1 (Amplified)* 2. Cell line MDA-453 (Amplified) 3. Cell line MCF-7 (Not amplified) 4. Cell line BT474 (Amplified)
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationHER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer
P A T H O L O G Y HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer FROM CERTAINTY COMES TRUST For in vitro diagnostic use HER2 CISH pharmdx Kit HER2 CISH pharmdx Kit is intended for dual-color
More information1.5. Research Areas Treatment Selection
1.5. Research Areas Cancer biomarker research embraces many areas of study, including tumorigenesis, metastasis, clinical trial and surrogate endpoints, cell isolation, target identification, drug resistance,
More informationHER2 ISH (BRISH or FISH)
Assessment Run H14 2018 HER2 ISH (BRISH or FISH) Material Table 1. Content of the multi-block used for the NordiQC HER2 ISH assessment, run H14 HER2 IHC* IHC score Dual - SISH** FISH*** FISH*** HER2/chr17
More informationAssessment Run C1 2017
Assessment Run C1 2017 PD-L1 The first assessment in this new NordiQC Companion module C1 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories to identify patients
More informationWorkflow. Connecting the Pieces For Total Patient Care
Workflow Connecting the Pieces For Total Patient Care Biocare provides a full line of IHC and molecular pathology products for cancer and infectious disease diagnosis. From a full range of equipment: including
More informationDetermination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined?
Anatomic Pathology / FISH f o r HER2: Wh e n to Use Ch r o m o s o m e 17 Determination of HER2 Amplification by In Situ Hybridization When Should Chromosome 17 Also Be Determined? John M.S. Bartlett,
More informationPD-L1 Analyte Control DR
Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1
More informationCorrelation Between GATA-3, Ki67 and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia
Cancer Research Journal 2016; 4(3): 43-47 http://www.sciencepublishinggroup.com/j/crj doi: 10.11648/j.crj.20160403.11 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online) Correlation Between GATA-3, Ki67
More informationA Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer
Elmer ress Original Article World J Oncol. 2017;8(3):71-75 A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer Hui Hu a, Wei Wei a, Xin Yi a, Ling Xin
More informationClinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,
More informationGuideline. Associated Documents ASCO CAP 2018 GUIDELINES and SUPPLEMENTS -
Guideline Subject: ASCO CAP 2018 HER2 Testing for Breast Cancer Guidelines - Recommendations for Practice in Australasia Approval Date: December 2018 Review Date: December 2022 Review By: HER2 testing
More information2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #449 (NQF 1857): HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies National Quality Strategy Domain: Efficiency and Cost Reduction 2017 OPTIONS
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationInstant Quality FISH. The name says it all.
COMPANION DIAGNOSTICS Instant Quality FISH Instant Quality FISH. The name says it all. IQ: Instant Quality every time. Breast carcinoma stained with : Triple filter showing Blue DAPI colors nuclei, FITC
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #449 (NQF 1857): HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies National Quality Strategy Domain: Efficiency and Cost Reduction Meaningful
More informationVENTANA ALK (D5F3) Rabbit Monoclonal Primary Antibody. ALK IHC Biomarker Testing Aiding in patient diagnosis
VENTANA (D5F3) Rabbit Monoclonal Primary Antibody IHC Biomarker Testing Aiding in patient diagnosis 2 IHC Biomarker Testing Lung cancer is the leading cause of death Lung cancer is the most prevalent form
More informationNordiQC External Quality Assurance in Immunohistochemistry
NordiQC External Quality Assurance in Immunohistochemistry Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark AALBORG (~ 200.000 inhabitants)
More informationVENTANA PD-L1 (SP142) Assay
VENTANA (SP142) Assay Guiding immunotherapy Hiker s path: VENTANA (SP142) Assay on urothelial carcinoma tissue Location: Point Conception, CA VENTANA (SP142) Assay Assess UC patient benefit from TECENTRIQ
More informationImmunohistochemistry in Breast Pathology- Brief Overview of the Technique and Applications in Breast Pathology
SMGr up Immunohistochemistry in Breast Pathology- Brief Overview of the Technique and Applications in Breast Pathology Bhanumathi K Rao 1 * 1 Department of Biochemistry, JSS Medical College, a constituent
More informationNIH Public Access Author Manuscript Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 January 1.
NIH Public Access Author Manuscript Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 January ; 19(1): 144 147. doi:10.1158/1055-9965.epi-09-0807. Feasibility Study for Collection
More informationMonitoring Metastatic Breast Cancer with Serum HER-2/neu: Individual Patient Profiles
Siemens Healthcare Diagnostics, a global leader in clinical diagnostics, provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the
More informationMEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,
More informationIntroduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd
Breast Cancer Res Treat (2017) 164:133 138 DOI 10.1007/s10549-017-4220-x EPIDEMIOLOGY Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients
More informationAssessment Run GATA3
Assessment Run 44 2015 GATA3 Material The slide to be stained for GATA3 comprised: 1. Tonsil 2. Kidney, 3. Urothelial carcinoma, 4. Breast ductal carcinoma, 5. Colon adenocarcinoma All tissues were fixed
More informationIdentifying ALK+ NSCLC patients for targeted treatment
VENTANA (D5F3) CDx Assay Identifying + NSCLC patients for targeted treatment VENTANA (D5F3) CDx Assay Identify + NSCLC patients eligible for treatment with XORI, ZYKADIA or ALECENSA NSCLC tissue samples
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #450 (NQF 1858): Trastuzumab Received By Patients With AJCC Stage I (T1c) III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy National Quality Strategy Domain: Effective Clinical
More informationLow ER+ Breast Cancer. Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD ABSTRACT
Low ER+ Breast Cancer Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD From the Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA.
More informationImage analysis in IHC overview, considerations and applications
Image analysis in IHC overview, considerations and applications Rasmus Røge, MD, Institute of Pathology, Aalborg University Hospital NordiQC workshop September 2016 Aalborg, Denmark Outline Theory Image
More informationAssessment Run C3 2018
Assessment Run C3 2018 PD-L1 Amended version May 14 th 2018 The third assessment in NordiQC Companion module C3 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment B25 208 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Tonsil < 2-5% Weak to strong
More informationEvaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters
Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters Mehdi Farzadnia, Naser TayyebiMeibodi, Fatemeh HomayiShandiz,
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationOn May 4 and 5, 2002, the College of American Pathologists
College of American Pathologists Conference Conference Summary, Strategic Science Symposium Her-2/neu Testing of Breast Cancer Patients in Clinical Practice Richard J. Zarbo, MD, DMD; M. Elizabeth H. Hammond,
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationQuality Assurance in Immunohistochemistry: Experiences from NordiQC
Nordic immunohistochemical Quality Control 2 Quality Assurance in Immunohistochemistry: Experiences from NordiQC Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg University Hospital Aalborg,
More informationAdjuvan Chemotherapy in Breast Cancer
Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality
More informationVersion 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-
Introduction: These guidelines represent systematically developed statements to assist in the provision of quality assured HER2 testing in breast and gastric/ gastro-oesophageal carcinoma. They are based
More informationVENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLC
VENTANA (SP142) Assay Guiding immunotherapy in NSCLC Hiker s path: VENTANA (SP142) Assay on non-small cell lung cancer tissue Location: Point Conception, CA VENTANA (SP142) Assay Assess NSCLC patient benefit
More informationOptimal algorithm for HER2 testing
Optimal algorithm for HER2 testing The revised definition of IHC 2+ (equivocal) is invasive breast cancer with Weak to moderate complete membrane staining observed in >10% of tumor cells. (see Figure 1
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationPathology Report Patient Companion Guide
Pathology Report Patient Companion Guide Breast Cancer - Understanding Your Pathology Report Pathology Reports can be overwhelming. They contain scientific terms that are unfamiliar and might be a bit
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationHER2/neu Evaluation of Breast Cancer in 2019
HER2/neu Evaluation of Breast Cancer in 2019 A.A. Sahin, M.D. Professor of Pathology and Translation Molecular Pathology Section Chief of Breast Pathology ERBB2 (HER2) Background 185-kDa membrane protein
More informationKi-67 is a biological tumor marker that reflects tumor
Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens Soomin Ahn, MD; Junghye Lee, MD; Min-Sun Cho, MD, PhD; Sanghui Park, MD, PhD; Sun Hee Sung, MD, PhD Context.
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationThe impact of proficiency testing on lab immunoassays
The impact of proficiency testing on lab immunoassays Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark Nordic Immunohistochemical Quality
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast Version: Template Posting Date: January 2018 Includes requirements from the 2017 CAP Accreditation
More informationDOUBLE STAINS. Toll-Free: Direct:
DOUBLE STAINS CD61 + CD71 DAB Brown: CD61 Alk. Phos. Red: CD71 Bone Marrow DAB Brown: Megakaryocytes Alk. Phos. Red: Erythroid Precursors 400x CD61 (2f2) 0.1 ml concentrate............. 161M-14 0.5 ml
More informationIs adjuvant chemotherapy necessary for Luminal A-like breast cancer?
JBUON 2018; 23(4): 877-882 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?
More informationBradley M Turner MD, MPH, MHA. Assistant Professor University of Rochester Department of Pathology and Laboratory Medicine
Bradley M Turner MD, MPH, MHA Assistant Professor University of Rochester Department of Pathology and Laboratory Medicine My real job!!! I have nothing to disclose although Oncotype Dx year end revenues
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationA new way of looking at breast cancer tumour biology
A new way of looking at breast cancer tumour biology Contents Intrinsic subtypes of breast cancer 3 Gene expression assays 3 Basis of the Prosigna test 4 Information provided by Prosigna 5 The accuracy
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More informationHER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade
Anatomic Pathology / HER2/NEU AMPLIFICATION IN BREAST CANCER HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade Elise R. Hoff, MD, Raymond R. Tubbs, DO, Jonathan L. Myles, MD,
More informationResearch Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
SAGE-Hindawi Access to Research International Breast Cancer Volume 20, Article ID 47957, 4 pages doi:0.406/20/47957 Research Article Stromal Expression of CD0 in Invasive Breast Carcinoma and Its Correlation
More informationMinimizing Errors in Diagnostic Pathology
Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville Medical Director, Shands Jacksonville Breast Health Center
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationPriti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract
Anatomic Pathology / DUAL- VS SINGLE-COLOR SCORING IN IMMUNOHISTOCHEMICAL AND FISH HER-2 TESTING HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization
More informationHer-2/neu expression and its correlation with ER status and various clinicopathological parameters
Original Research Article DOI: 10.5958/2394-6792.2016.00106.X Her-2/neu expression and its correlation with ER status and various clinicopathological parameters Kriti Chauhan 1,*, Monika Garg 2, Abhimanyu
More informationCarcinome du sein Biologie moléculaire. Thomas McKee Service de Pathologie Clinique Genève
Carcinome du sein Biologie moléculaire Thomas McKee Service de Pathologie Clinique Genève Pathology Diagnostic Prognostic information Predictive information The information provided depends on the available
More informationHeather M. Gage, MD, Avanti Rangnekar, Robert E. Heidel, PhD, Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, PhD
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF CLINICAL TRIALS Heather M. Gage, MD, Avanti Rangnekar,
More informationEstrogen receptor (ER)
Assessment Run B7 204 Estrogen receptor (ER) Material The slide to be stained for ER comprised: No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Breast carcinoma 0%
More information